Posts

What Boosts Adherence to GLP-1s?

GLP-1s sometimes cause unpleasant side effects that can lead to nonadherence and discontinuation, but some patients stay the course anyway. What factors motivate them not to give up? Medscape Medical News source https://www.medscape.com/viewarticle/what-boosts-adherence-glp-1s-2026a100066e?src=rss

Stem Cell Therapy Safe, Feasible in Spina Bifida

A first-in-human trial shows the feasibility and safety of delivering placenta-derived stem cells during prenatal myelomeningocele repair. Medscape Medical News source https://www.medscape.com/viewarticle/first-human-trial-supports-safety-feasibility-stem-cell-2026a1000667?src=rss

Lymphoma Tx Linked to Mild Photodistributed Skin Reactions

About 1 in 5 patients with B-cell lymphoma treated with loncastuximab develop skin-related adverse events, particularly photodistributed erythematous patches, a study finds. Medscape Medical News source https://www.medscape.com/viewarticle/lymphoma-treatment-linked-mild-photodistributed-skin-2026a100065u?src=rss

Nearly a Third of US Youth Have Prediabetes or Diabetes

Nearly 1 in 3 US adolescents have prediabetes or type 2 diabetes, with abdominal adiposity being the strongest independent predictor, analysis of national survey data from 2021 to 2023 shows. Medscape Medical News source https://www.medscape.com/viewarticle/nearly-third-us-youth-have-prediabetes-or-diabetes-2026a1000617?src=rss

Company Files for Approval of New Pustular Psoriasis Rx

Imsidolimab is a monoclonal antibody that inhibits interleukin-36 receptor signaling and is administered intravenously. Medscape Medical News source https://www.medscape.com/viewarticle/company-files-approval-biologic-treating-generalized-2026a100060x?src=rss

ChatGPT Excels at Classifying Ultraprocessed Foods

ChatGPT accurately classifies foods by processing level and detects ultraprocessed items, which may help automate and improve future dietary research. Medscape Medical News source https://www.medscape.com/viewarticle/chatgpt-excels-classifying-ultraprocessed-foods-2026a10005vr?src=rss

Long-Acting HIV Drug Switch Shows No Major Metabolic Impact

In patients with HIV infection, a switch to long acting cabotegravir plus rilpivirine shows no clinically meaningful changes in body composition or adverse metabolic effects over 48 weeks. Medscape Medical News source https://www.medscape.com/viewarticle/long-acting-hiv-drug-switch-shows-no-major-metabolic-impact-2026a10005vf?src=rss